title: Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex.
abstract: Galanin is a recently isolated neuropeptide that is of particular interest in dementing disorders because of its known colocalization with choline acetyltransferase in magnocellular neurons of the basal nucleus of Meynert. These neurons degenerate in Alzheimer's disease, and there is a corresponding deficiency of cortical choline acetyltransferase activity. In the present study, galanin-like immunoreactivity was measured in the postmortem cerebral cortex and hippocampus of 10 controls and 14 patients who had had Alzheimer's disease. Significant reductions of choline acetyltransferase activity (50-60%) were found in all regions examined; however, there was no significant effect on concentrations of galanin-like immunoreactivity. Similar measurements were made in postmortem tissues of 12 control and 13 demented Parkinsonian patients who had had Alzheimer-type cortical pathology. Choline acetyltransferase activity was again significantly decreased in all regions examined but there were no significant reductions in galanin-like immunoreactivity. Experimental lesions of the fornix in rats produced parallel significantly correlated reductions of both choline acetyltransferase activity and galanin-like immunoreactivity in the hippocampus. Galanin-like immunoreactivity in the human hypothalamus consisted of two molecular-weight species on gel-permeation chromatography, and two forms were resolved by reverse-phase HPLC. The paradoxical preservation of galanin-like immunoreactivity, despite depletion of the activity of choline acetyltransferase, with which it is colocalized, is as yet unexplained. Recent studies have shown that galanin inhibits both acetylcholine release in the hippocampus and memory acquisition; therefore, preserved galanin may exacerbate the cholinergic and cognitive deficits that accompany dementia.
authors: Department of Neurology, Massachusetts General Hospital, Boston.
authors: M F
authors: MF
authors: Beal
authors: R A
authors: RA
authors: Clevens
authors: G K
authors: GK
authors: Chattha
authors: U M
authors: UM
authors: MacGarvey
authors: M F
authors: MF
authors: Mazurek
authors: S M
authors: SM
authors: Gabriel
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism*; D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005260:Female; D019004:Galanin; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism*; D017378:Quinolinic Acid; D011805:Quinolinic Acids / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013377:Substantia Innominata / Q000187:drug effects / Q000502:physiology
chemical_list: D010455:Peptides; D011805:Quinolinic Acids; D019004:Galanin; D002795:Choline O-Acetyltransferase; D017378:Quinolinic Acid